{"id":"ibi343","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IBI343 functions as a PD-1/TGF-β bispecific antibody designed to overcome immunosuppression in the tumor microenvironment. By blocking PD-1 signaling while simultaneously neutralizing TGF-β, the drug aims to reinvigorate exhausted T cells and reduce the immunosuppressive effects of TGF-β, thereby enhancing anti-tumor immune responses.","oneSentence":"IBI343 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:19.391Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (in development)"}]},"trialDetails":[{"nctId":"NCT07483554","phase":"PHASE2","title":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-03-25","conditions":"CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":389},{"nctId":"NCT07483567","phase":"PHASE2","title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-03-30","conditions":"CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT07415525","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-01","conditions":"Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT05458219","phase":"PHASE1","title":"A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-10-26","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors","enrollment":470},{"nctId":"NCT06770439","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-18","conditions":"Advanced Pancreatic Cancers","enrollment":64},{"nctId":"NCT06238843","phase":"PHASE3","title":"A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2024-06-30","conditions":"Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":450},{"nctId":"NCT07066098","phase":"PHASE3","title":"A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-08-04","conditions":"Pancreatic Cancer","enrollment":201},{"nctId":"NCT07025889","phase":"PHASE1, PHASE2","title":"IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-02","conditions":"Gastric Cancer","enrollment":55},{"nctId":"NCT06321913","phase":"PHASE2","title":"Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-03-15","conditions":"Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arcotatug Tavatecan","AG regimen"],"phase":"phase_3","status":"active","brandName":"IBI343","genericName":"IBI343","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IBI343 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. Used for Non-small cell lung cancer, Other solid tumors (in development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}